DYNAMIC ELASTOGRAPHY OF THE LIVER IN THE ASSESSMENT OF EFFICACY OF TREATMENT OF PATIENTS WITH HEPATIC CIRRHOSIS OF VARIOUS ETIOLOGY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The worldwide high prevalence of hepatic cirrhosis (HC) of various etiologies with unfavorable fatal outcomes dictates the need to search for the modern and available methods for evaluating the effectiveness of the treatment of such patients. The article considers the results of last 5-year study dedicated to this issue. The results of the examination of 194 patients with HC of various etiologies aged age 18 to 75 years are presented: 56 patients with HC of alcoholic etiology, 48 - with HC as outcome of non-alcoholic fatty liver disease, 53 and 23 patients with HC as outcome of chronic hepatitis C and B, respectively, and 14 - with HC as outcome of co-infection of hepatitis B+D. The study analyzed the effect of the therapy on the progression of HC and its complications according to the elastography of the liver. Presence or absence of treatment was taken into account. Close correlation of clinical manifestations of the disease in patients with HC of various etiologies and liver density values according elastography of the liver depending on the presence or absence of the treatment was found.

Full Text

Restricted Access

About the authors

N. Yu Stukova

NGHCI CCH № 2 n.a. O.N. Semashko of JSC Russian Railways; SBEI HPE "Moscow State Medical Stomatological University n.a. A.I. Evdokimov of RMH

Email: natastu@mail.ru
astroenterologist, nutritionist, postgraduate student at the the Department of Propedeutics of Internal Diseases and Gastroenterology

I. V Maev

SBEI HPE "Moscow State Medical Stomatological University n.a. A.I. Evdokimov of RMH

E. A Krasnyakova

LLC "Medical Center", Moscow

S. V Morozov

FSBI "Scientific Research Institute of Nutrition"

Yu. A. Kucheryavy

NGHCI CCH № 2 n.a. O.N. Semashko of JSC Russian Railways; SBEI HPE "Moscow State Medical Stomatological University n.a. A.I. Evdokimov of RMH

References

  1. All-Party Parliamentary Hepatology Group (APPHG). Liver disease: today's complacency, tomorrow's catastrophe. The All-Party Parliamentary Hepatology Group (APPHG) inquiry into improving outcomes in liver disease. UK: All-Party Parliamentary Hepatology Group (APPHG), 2014.
  2. Neff G.W, Kemmer N., Duncan C., Alsina A. Update on the management of cirrhosis -focus on cost-effective preventative strategies. Clinicoecon. Outcomes Res. 2013; 12; 5: 143-52.
  3. D'Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 2006; 44: 217-31.
  4. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2014; 60(2): 392-420.
  5. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J. Hepatol. 2015; 63(1): 199-236.
  6. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57(1): 167-85.
  7. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J. Hepatol. 2012; 57(2): 399-420.
  8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J. Hepatol. 2009; 51(2): 237-67.
  9. American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J. Hepatol. 2014; 61(3): 642-59.
  10. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J. Hepatol. 2010; 53(3): 397-417.
  11. Маевская М.В., Федосьина Е.А. Лечение осложнений цирроза печени: методические рекомендации для врачей. Под ред. В.Т. Ивашкина. М., 2012. 64 с.
  12. Wiesner R., Edwards E., Freeman R., Harper A., Kim R., Kamath P, Kremers W., Lake J., Howard T., Merion R.M., Wolfe R.A., Krom R.; United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003; 124(1): 91-6.
  13. Durand F., Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J. Hepatol. 2005; 42: 100-7.
  14. Valery P.C., Powell E., Moses N., Volk M.L., McPhail S.M., Clark P.J., Martin J. Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. BMJ Open. 2015; 5: e007451.
  15. Fraquelli M., Rigamonti C., Casazza G., Conte D., Donato M.F., Ronchi G., Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007; 56: 968-73.
  16. Morozov S.V., Trufanova Y.M., Isakov V.A., Kaganov B.S. The reproducibility of transient elastography in patients with chronic liver diseases. Gastroenterology. 2008; 134(4) (Suppl. 1): A-310. Материалы DDW 2008, San Diego.
  17. Grando-Lemaire V., De Ledinghen V., Bourcier V., et al. Liver stiffness measurement (LSM) as a tool to measure liver fibrosis in treated patients with chronic hepatitis C (CHC). J. Hepatol. 2006; 44(Suppl.): S214.
  18. Andrews G., Jenkins R. (eds) (1999). Management of Mental Disorders (UK Edition). London: World Health Organization Collaborating Centre for Mental Health and Substance Abuse; Goldberg, D., et al. (2000). WHO guide to mental health in primary care (UK ed.). London: WHO Collaborating Centre for Research and Training for Mental Health.
  19. Williams N. The CAGE questionnaire. Occup. Med. (Lond). 2014; 64(6): 473-74.
  20. Babor T.F., Higgins-Biddle J.C., Saunders J.B., Monteiro M.G.The Alcohol Use Disorders Identification Test. Guidelines for Use in Primary Care. Geneva: World Health Organization. 2001.
  21. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М., 2002. 312 с.
  22. Talwalkar J.A., Kurtz D.M., Schoenleber S.J., West C.P, Montori V.M. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2007; 5(10): 1214-20.
  23. Castera L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., Darriet M., Couzigou P., De Lédinghen V. Prospective Comparison of Transient Elastography, Fibrotest, APRI, and Liver Biopsy for the Assessment of Fibrosis in Chronic Hepatitis C. Gastroenterology. 2005; 128: 343-50.
  24. Морозов С.В., Труфанова Ю.М., Павлова Т.В. и др. Применение эластографии для определения выраженности фиброза печени: результаты регистрационного исследования в России. Клин. и эксперим. гастроэнтерол. 2008; 2: 2-14.
  25. Морозов С.В., Кучерявый Ю.А., Стукова Н.Ю., Краснякова Е.А. Непрямая ультразвуковая эластография печени: от диагностики фиброза печени - к контролю над лечением. Доказательная гастроэнтерология. 2013; 2: 31-7.
  26. Стукова Н.Ю., Краснякова Е.А., Морозов С.В., Кучерявый Ю.А., Маевская Е.А., Маев И.В. Применение ультразвуковой эластографии для оценки риска развития осложнений цирроза печени. Клинические перспективы гастроэнтерологии, гепатологии. 2015; 6: 39-48.
  27. Foucher J., Chanteloup E., Vergniol J., Castéra L., Le Bail B., Adhoute X., Bertet J., Couzigou P., de Lédinghen V. Diagnosis of cirrhosis by transient elastography (Fibroscan(R)): a prospective study. Gut. 2006; 55: 403-8.
  28. Fraquelli M., Rigamonti C., Casazza G., Conte D., Donato M.F., Ronchi G., Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007; 56: 968-73.
  29. Morozov S.V., Trufanova Y.M., Isakov V.A., Kaganov B.S. The reproducibility of transient elastography in patients with chronic liver diseases. Gastroenterology. 2008; 134(4) (Suppl. 1): A-310.
  30. Njei B., McCarty T.R., Garcia-Tsao G. Betablockers in patients with cirrhosis and ascites: type of beta-blocker matters. Gut. 2016: pii: gutjnl-2016-312129.
  31. Dimache M., Gîrleanu I., Carpov E., Trifan A., Stanciu C. Nonselective beta-blockers in patients with cirrhosis: «the therapeutic window». Rev. Med. Chir.Soc. Med. Nat. Iasi. 2016; 120(1): 23-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies